INTERBRI · CHINA MARKET ACCESS FOR MEDICAL DEVICES China-focused support. Clear scope. Accountable coordination.
Regulatory Analysis

China Legal Agent for Medical Devices: Duties, Requirements and How to Change One

10 min readBased on current regulations

Every overseas manufacturer that registers or files a device in China must designate a China legal agent — an enterprise legal person domiciled in China, designated by the foreign registrant or filer to handle regulatory matters and to assist in performing the registrant’s statutory obligations. This article explains the role’s legal basis, what it does in practice, how it differs from a distributor and from the EU authorized representative, and how to change agents without creating a compliance gap.

The role is anchored in China’s core device regulations:

  • Decree No. 739, Articles 15 & 16 — overseas filers and applicants submit filing and registration materials to the Chinese authorities through the enterprise legal person they designate in China, together with proof of market authorization in their home jurisdiction;
  • Decree No. 739, Article 20 — registrants/filers must maintain a QMS, run post-market research and risk control, perform adverse event monitoring and re-evaluation, and maintain traceability and recall systems; the designated China enterprise legal person shall assist in performing these obligations;
  • Decree No. 739, Article 57 — imported devices must carry Chinese labels and IFUs that state the name, address and contact details of the designated China entity;
  • Order No. 47, Article 14 — the agent handles registration and filing matters and assists the overseas registrant in meeting its obligations and legal liabilities;
  • Order No. 47, Article 102 — the NMPA forwards agent information to the provincial regulator, which supervises agents in its region.

2. What the entity must be

Current regulations require the agent to be an enterprise legal person domiciled in China (公司法人). Beyond that, the statutes do not prescribe a specific license for acting as an agent — the decisive factors are practical: regulatory competence, Chinese/English bilingual capability, reliable processes for vigilance and recall coordination, and the ability to be reachable by the regulator. Note that the agent’s information is registered with the authorities and supervised by the provincial drug administration where it is located, so continuity and accountability matter.

3. What the agent does in practice

Across the product lifecycle, the agent’s work concentrates in four areas:

  • Submission liaison — filing and registering products with the NMPA, receiving deficiency letters, coordinating responses, handling change registrations and record-level change filings, and renewal applications in the 6-month window before certificate expiry;
  • Adverse event monitoring — under the Measures for Adverse Event Monitoring and Re-evaluation (SAMR/NHC Order No. 1, 2019), the agent of an overseas holder undertakes the AE monitoring work for imported devices sold in China (Article 3), maintains an information transfer mechanism with the holder (Article 15), reports foreign serious events within 30 days (Article 27) and foreign control measures within 24 hours (Article 53). Individual reports: deaths within 7 days, serious injuries within 20 days (Article 25);
  • Recall & risk control coordination — assisting the holder’s recall and risk-control obligations under Decree No. 739, Articles 66–67;
  • Regulator communication — being the reachable, accountable counterpart for the NMPA and the provincial authorities.

Liability stays with the overseas registrant: the agent assists the registrant in fulfilling obligations — it does not replace the registrant as the responsible party. That said, the agent has its own exposure: failing to perform agent duties can bring warnings and fines from RMB 50,000 up to RMB 500,000 for serious cases (Decree No. 739, Article 98), and an overseas registrant that refuses to comply with an administrative penalty decision can face a 10-year import ban.

4. China agent vs. EU authorized representative vs. distributor

These three roles are frequently confused. They are different legal constructs under different jurisdictions’ laws:

Table: 4. China agent vs. EU authorized representative vs. distributor
AspectChina legal agent (境内代理人)EU authorized representativeDistributor
Governing lawChina (Decree 739; Order 47)EU (MDR Article 11)Contract & local distribution rules
Why it existsMandatory regulatory counterpart for the overseas registrant/filer with the NMPARegulatory point of contact for EU authorities, designated in writing by the EU manufacturerCommercial: buys and sells products
Appears on product labelingYes — Chinese labels/IFU must state the agent’s name, address and contactYes — CE-marked devices must show the ARNo
Submits registrationsYes — files and registers on behalf of the overseas holderNo — does not file technical documentation for the manufacturerNo
Post-market roleAssists vigilance, recall and re-evaluation duties; runs AE monitoring for imported devicesVerifies CE technical documentation, contact point for complaintsCooperates in vigilance/recalls per supply contracts
Can be a distributor?Yes, if it is a China enterprise legal person — but separating the two roles protects your registration from commercial disputesSeparate role under EU law—

The practical takeaway: appointing your distributor as your China legal agent ties your regulatory identity to a commercial relationship. If the distribution agreement ends, the registered details, label stock and regulator communications all have to move — often mid-product-lifecycle. Many manufacturers therefore keep the agent role independent from sales.

5. Appointing an agent: what a good agreement covers

The regulations set the role; the agreement sets the working relationship. A robust agent agreement covers at least: scope and term; the information-transfer mechanism required by Order No. 1, Article 15; who prepares and signs submission documents; vigilance and recall procedures with response times; change and renewal handling; document custody (who keeps the dossier and correspondence); termination and transition assistance; and language of records. Ask for a sample checklist — we maintain one internally.

Agent changes are more common than many expect — distributor transitions, entity restructurings or service quality all trigger them. The good news: an agent name/address change is a record-level change (备案事项), not a full change registration: it is filed with the original authority within 30 days of the change (Order No. 47, Article 79), and the registration certificate itself is not reissued. The operational work is in the transition, not the filing:

  1. Execute the tripartite or bilateral handover: new agent agreement signed, old agreement terminated with a defined cut-off date;
  2. Transfer regulatory assets: registration certificates and attachments, dossier copies, correspondence, UDI records, adverse event monitoring records (retention rules apply), open deficiency letters;
  3. File the record-level change with the original acceptance authority within 30 days;
  4. Update Chinese labels/IFU artwork so the agent block matches the new agent — coordinate with stock and reprint timing;
  5. Verify continuity of vigilance reporting: no deaths or serious-injury reports may fall into the gap between agents.

Industry experience puts a clean agent transition at around two months end to end; complex portfolios take longer. Plan the overlap deliberately rather than letting the reporting duty lapse.

This article summarizes the agent provisions of Decree No. 739, Order No. 47 and Order No. 1 (2019). It is general information, not legal advice; current official publications always prevail. If you are appointing or replacing a China legal agent, ask us for a transition plan.
Back to the Regulation Library